X0306 4 2018-03-02 0001289340 Stereotaxis, Inc. STXS 0001267959 MIDDLETON FRED A C/O STEREOTAXIS, INC. 4320 FOREST PARK AVENUE, SUITE 100 ST. LOUIS MO 63108 1 0 0 0 Common Stock 2018-03-02 4 X 0 153846 .28 A 303528 D Common Stock 1107189 I Sanderling Venture Partners VI Co-Investment Fund, L.P. Common Stock 6358 I Sanderling VI Limited Partnership Common Stock 5335 I Sanderling VI Beteiligungs GmbH & Co. KG Common Stock 53275 I Sanderling IV Biomedical Co-Investment Fund, L.P. Common Stock 11097 I Sanderling V Beteiligungs GmbH & Co. KG Common Stock 39716 I Sanderling V Biomedical Co-Investment Fund, L.P. Common Stock 11956 I Sanderling V Limited Partnership Common Stock 67790 I Sanderling Venture Partners V Co-Investment Fund, L.P. Common Stock 22451 I Sanderling Venture Partners IV Co-Investment Fund Common Stock Warrant (right to buy) .70 2018-03-01 4 D 0 153846 D 2016-09-29 2021-09-29 Common Stock 153846 0 D Common Stock Warrant (right to buy) .28 2018-03-01 4 A 0 153846 A 2016-09-29 2021-09-29 Common Stock 153846 153846 D Common Stock Warrant (right to buy) .28 2018-03-02 4 X 0 153846 0 D 2016-09-29 2021-09-29 Common Stock 153846 0 D On February 28, 2018, the issuer and certain holders of outstanding warrants issued pursuant to the Stock Purchase Agreement dated September 26, 2016, including the reporting person, entered into an amendment to the warrants. The amendment provided that the exercise price of the warrants would be reduced for a limited period of time, provided that at least $6 million of warrants was exercised during the limited period. This condition was satisfied on March 1, 2018. The transactions reported in the first two lines of Table II above report the amendment of the warrant to temporarily reduce the exercise price from $0.70 per share to $0.28 per share. The amendment is reported as the disposition of the old warrant and the acquisition of a new one. The amendment to the warrant was approved by a transaction committee consisting solely of independent directors for purposes of Rules 16b-3(d) and (e). /s/ Karen Witte Duros, Attorney-in-Fact 2018-03-05